Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Mbrx save search
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-12-07 (Crawled : 14:00) - prnewswire.com
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 3.88%
H: 12.69%
C: 11.19%
wp1122 treatment fda designation granted fast track designation glioblastoma
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-09-06 (Crawled : 13:00) - prnewswire.com
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 0.0%
H: 1.66%
C: -3.5%
wp1122 treatment fda designation drug glioblastoma
Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2021-12-01 (Crawled : 13:30) - prnewswire.com
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 1.22%
H: 10.14%
C: 5.8%
treatment fda phase 1 phase 2 glioblastoma
WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
Published: 2021-07-12 (Crawled : 12:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 1.09%
H: 0.94%
C: -2.48%
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 5.28%
H: 0.0%
C: -0.56%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 7.18%
H: 2.06%
C: 2.06%
berubicin treatment fda fda fast track fast track fast track designation designation glioblastoma
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
Published: 2021-04-14 (Crawled : 12:15) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 7.73%
H: 1.79%
C: -5.38%
disease treatment fda rpd wp1066 ependymoma designation rare
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
Published: 2021-03-30 (Crawled : 12:00) - prnewswire.com
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 21.89%
H: 5.76%
C: -5.76%
treatment fda fast track fda approval approval fast track designation designation
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Published: 2020-12-29 (Crawled : 13:00) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 8.84%
H: 2.56%
C: -13.64%
drug fda designation soft tissue
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 5.13%
H: 0.61%
C: -3.66%
fda
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
Published: 2020-12-01 (Crawled : 22:00) - biospace.com/
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 41.03%
H: 10.91%
C: -10.0%
disease fda wp1066 approval fda approval designation rare
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.